Insights
Search Results
Case Studies
8.14.26
How Wilson Sonsini Helped Soleno Therapeutics Position Itself as an Attractive Acquisition Target
Soleno Therapeutics, a Neurocrine Biosciences company, focuses on the treatment of rare diseases by identifying, developing, and commercializing novel therapeutics. Its lead commercial program addresses Prader-Willi syndrome (PWS), which occurs in approximately one in every 15,000 live births. One of the common symptoms of PWS is hyperphagia, a chronic and life-threatening condition characterized by an intense, persistent sensation of hunger.
News Articles
8.12.26
Farah Gerdes Honored as a "Distinguished Leader" for 2026 New England Legal Awards
On August 10, 2026, Wilson Sonsini attorney Farah Gerdes was named among the winners of the “Distinguished Leaders” category for Law.com’s 2026 New England Legal Awards. The awards honor attorneys and firms from Connecticut, Maine, Vermont, New Hampshire, Massachusetts, and Rhode Island.
News Articles
8.04.26
San Diego Business Journal Names Nellie Brutocao Among 2026 "Leaders of Influence in Technology"
On August 3, 2026, Wilson Sonsini partner Nellie Brutocao was honored among the 2026 “Leaders of Influence in Technology” in San Diego Business Journal’s special supplement.
Client Highlights
7.16.26
Wilson Sonsini Advises NIPRO on Expanded Partnership with Linear Health Sciences
On July 13, 2026, Linear Health Sciences announced that Japanese medical device manufacturer NIPRO will begin distributing its Orchid Safety Release Valve (SRV) in the Japanese market beginning July 22, 2026. The device is designed to prevent unintentional IV catheter dislodgement by introducing a mechanism that safely disconnects when excessive force is applied. Wilson Sonsini Goodrich & Rosati advised NIPRO on the transaction.
Client Highlights
7.08.26
Wilson Sonsini Advises Insilico on Collaboration with Takeda
On July 1, 2026, Insilico Medicine (Insilico), a clinical-stage biotechnology company powered by generative artificial intelligence and automation, announced a strategic collaboration agreement with Takeda to use Insilico’s proprietary end-to-end platform, Pharma.AI, to advance drug candidates across various therapeutic areas, with a potential initial value of $600 million. Insilico will lead drug discovery, while Takeda will further development, including advancing candidates past clinical trials.
Client Highlights
6.22.26
Firm Advises Denali Therapeutics on Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
On June 18, 2026, Denali Therapeutics, a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform, announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million. Wilson Sonsini Goodrich & Rosati advised Denali on the transaction.
Client Highlights
6.11.26
Wilson Sonsini Advises Adyen on $335 Million Acquisition of Orb
On June 11, 2026, Adyen N.V. (AMS: ADYEN), a global financial technology platform, announced it has entered into a definitive agreement to acquire enterprise billing platform Orb for $335 million. Upon closing, Orb will become an indirect, wholly owned subsidiary managed under an incubator model. The strategic intent is to eventually create a unified infrastructure experience for merchants across billing and payments.
Client Highlights
6.03.26
Wilson Sonsini Advises Luminopia on Licensing Agreement with ROHTO
On June 2, 2026, Luminopia, Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co., LTD, a Japanese multinational corporation specializing in consumer products and pharmaceuticals. Wilson Sonsini Goodrich & Rosati advised Luminopia on the transaction.
Client Highlights
4.09.26
Firm Advises Marvell Technology on Strategic Partnership and $2 Billion Investment from NVIDIA
On March 31, 2026, NVIDIA announced it has invested $2 billion in Marvell Technology as part of a strategic partnership to connect Marvell to the NVIDIA AI factory and AI-RAN ecosystem through NVIDIA NVLink Fusion™. This partnership offers customers building on NVIDIA architectures greater choice and flexibility in developing next-generation infrastructure. The companies will also collaborate on silicon photonics technology. Wilson Sonsini Goodrich & Rosati advised Marvell on the transaction.
Client Highlights
3.31.26
Wilson Sonsini Advises Insilico on Global R&D Collaboration with Lilly
On March 29, 2026, Insilico Medicine (Insilico), a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, announced a drug discovery collaboration with Eli Lilly and Company (Lilly) that uses Insilico's AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. Wilson Sonsini Goodrich & Rosati advised Insilico on the transaction.